Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Join us for Impact of RSV Infection on Cardiovascular System: Why Prevention Matters, featuring Dr. Yew Kuan Leong, Consultant Cardiologist & Internal Medicine Physician, Bukit Tinggi Medical Center, Klang, and Dr. Syed Ajmal Bin Syed Ali, Consultant Respiratory Physician & Interventional Pulmonologist, Sunway Medical Centre.
This webinar will explore the pathophysiological link between RSV infection and cardiovascular complications, and why timely prevention plays a critical role in protecting vulnerable populations.
Oct 7, Tuesday | 7.00 - 8.30pm
AREXVY [respiratory syncytial virus vaccine (adults)] Safety Information1:
AREXVY is contraindicated in anyone with hypersensitivity to the active substances or to any of the excipients.
In study participants 60 years of age and older, the most commonly reported adverse reactions were injection site pain (61%), fatigue (34%), myalgia (29%), headache (28%), and arthralgia (18%).
Before prescribing, please refer to the full prescribing information available here.
Reference:
- Arexvy Prescribing Information
Trade marks are owned by or licensed to the GSK group of companies.
PM-MY-RSA-WCNT-250008 12/25
